Semaglutide is a human glucagon-like peptide-1 (GLP-1) analogue, which promotes insulin secretion and inhibits glucagon secretion through a glucose concentration-dependent mechanism, which can make type 2 diabetes mellitus The patient's blood glucose level has improved significantly and the risk of hypoglycemia is low
Rebound Clinics DMV
Franzese, A., Iannilli, A., Mozzillo, E., Mastrandrea, V., & Bonora, E
Over 20,000 patients in Pakistan are benefiting from this innovative therapy, making a tangible difference in diabetes and improving quality of life

Drugs that may increase the risk of hypoglycemia : antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors Drugs that may decrease the blood glucose lowering effect: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones Drugs that may increase or decrease the blood glucose lowering effect : alcohol, beta-blockers, clonidine, lithium salts, and pentamidine Drugs that may blunt the signs and symptoms of hypoglycemia : beta-blockers, clonidine, guanethidine, and reserpine Please click here for Tresiba Prescribing Information
